NLRP3 and colitis: In an animal study of colitis, the use of 2-bromopalmitate (2-BP), a palmitoylation inhibitor, improved survival rates and reduced weight loss, indicating that regulating NLRP3 palmitoylation is a prospective therapeutic strategy for NLRP3-driven inflammatory diseases [20].